Pharma’s Biggest Blind Spot: Why 99.9% of Chemical Space Was Never Explored | Dr. Olga Nissan, Ph.D. - Vice President of Business Development, Evogene

Send us Fan MailPharma has only explored a tiny fraction - less than one-tenth of one percent - of all possible drug-like molecules. So the question is: what happens when AI suddenly opens up the other 99.9%?Dr. Olga Nissan, Ph.D. is Vice President of Business Development at Evogene ( https://evogene.com/ ) where she leads pharmaceutical partnerships for the company’s ChemPass AI generative chemistry platform - an advanced system designed to dramatically expand the searchable universe of drug-like molecules.With over 15 years of experience spanning biotech, pharma, and computational biology, Dr. Nissan operates at the intersection of science, strategy, and commercialization. Prior to Evogene, she was Co-Founder and CEO of Protica Bio, a precision oncology company focused on translating novel biological insights into therapeutic opportunities. Earlier in her career, she held scientific and operational roles at Teva Pharmaceutical Industries, as well as EcoPhage and BiomX, building expertise across microbiology, molecular biology, and translational R&D.Dr. Nissan has a strong track record of advancing technologies from early discovery through clinical and commercial partnerships, and of aligning cutting-edge innovation with the practical needs of pharmaceutical companies. She earned her Ph.D. and completed her postdoctoral training at the Weizmann Institute of Science.#DrugDiscovery #AIinPharma #GenerativeAI #Biotech #PharmaInnovation #ChemistryAI #MachineLearning #DrugDevelopment #PharmaceuticalIndustry #Bioinformatics #AIResearch #ChemPass #Evogene #ComputationalChemistry #FutureOfMedicine #DrugDesign #DeepLearning #HealthcareInnovation #BiotechNews #SciencePodcastSupport the show